Galantamine Tablet, Film Coated
Product Images NDC 68084-729
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 68084-729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Galantamine Hydrobromide Structural Formula (Structure)
Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Figure 1)
Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed (Figure 2)
Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Figure 3)
Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Figure 4)
Figure 5: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed (Figure 5)
Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Figure 6)
Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Figure 7)
Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed (Figure 8)
Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Figure 9)
Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Figure 10)
Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed (Figure 11)
Figure 12: Distribution Of Cibic-plus Ratings At Week 13 (Figure 12)
4 mg Galantamine Tablets Carton (4 mg Galantamine Tablets Carton)
4 mg Galantamine Tablet Blister (4 mg Galantamine Tablet Blister)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.